Maryland biotech company Emergent BioSolutions said on Thursday that it was approved by the U.S. Food and Drug Administration (FDA) to resume manufacturing of Johnson & Johnson’s COVID-19 vaccine at its Bayview plant in East Baltimore. The Gaithersburg-based company, which serves as a contract manufacturer for pharma companies, has an agreement with J&J to provide doses of its one-shot vaccine.
Image: Emergent Biosolutions’ Bayview facility. (Courtesy photo)
{iframe}https://technical.ly/baltimore/2021/07/29/emergent-restart/{/iframe}